Journal
EBIOMEDICINE
Volume 4, Issue -, Pages 138-145Publisher
ELSEVIER SCIENCE BV
DOI: 10.1016/j.ebiom.2016.01.007
Keywords
Cancer; Stem cell; CSC; EMT; Plasticity; Therapy; Resistance
Funding
- National Centre for the Replacement, Refinement and Reduction of Animals in Research (NC3Rs) [NC/L00061X/1, G0900799/1, NC/K500495/1] Funding Source: researchfish
- National Centre for the Replacement, Refinement and Reduction of Animals in Research [G0900799/1, NC/K500495/1, NC/L00061X/1] Funding Source: Medline
Ask authors/readers for more resources
Cancer stem cells (CSCs) drive tumour spread and therapeutic resistance, and can undergo epithelial-to-mesenchymal transition (EMT) and mesenchymal-to-epithelial transition (MET) to switch between epithelial and post-EMT sub-populations. Examining oral squamous cell carcinoma (OSCC), we now show that increased phenotypic plasticity, the ability to undergo EMT/MET, underlies increased CSC therapeutic resistance within both the epithelial and post-EMT sub-populations. The post-EMT CSCs that possess plasticity exhibit particularly enhanced therapeutic resistance and are defined by a CD44(high)EpCAM(low)/-CD24(+) cell surface marker profile. Treatment with TGF beta and retinoic acid (RA) enabled enrichment of this sub-population for therapeutic testing, through which the endoplasmic reticulum(ER) stressor and autophagy inhibitor Thapsigargin was shown to selectively target these cells. Demonstration of the link between phenotypic plasticity and therapeutic resistance, and development of an in vitro method for enrichment of a highly resistant CSC sub-population, provides an opportunity for the development of improved chemotherapeutic agents that can eliminate CSCs. (C) 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available